Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
Date:2/10/2011

curities during 2010 and a one-time $1.4 million loss recognized on auction rate securities in 2009.

2011 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $3 to $6 million in 2011. Revenue is expected to increase to approximately $75 to $80 million which includes amortization of up-front license fees of approximately $36 million and anticipated milestones earned under collaboration agreements of approximately $30 million. Expenses for 2011 should approximate $44 to $48 million. Net income for 2011 is expected to be $34 to $39 million, or $0.62 to $0.71 cents per share based on 55 million basic shares outstanding. The Company expects to end 2011 with approximately $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbott and Neurocrine requested an end of Phase II meeting last year and the companies are scheduled to meet with the FDA in March 2011. The Companies are currently preparing the briefing document for the FDA meeting. This document will encompass the entirety of the elagolix endometriosis program thus far including, twelve Phase I studies and six Phase II studies in over 1,000 subjects for up to six months of continuous treatment. Upon receipt of the written minutes of the March 2011 meeting, the Company will provide an update as to the timing around the elagolix clinical program.

Urocortin 2 UpdateThe Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is enrolling patients with Acute Decompensated Heart Failure in a Phase II study of urocortin 2, and has enrolled 39 patients as of mid-January, of a planned total patient population of 50.

Additionally, urocortin 2 studies are underway at the Centre for Cardiovascular Sciences at The University of Edinburgh through a British Heart Foundation grant. Nine studies are expec
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
2. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
10. Neurocrine Biosciences Amends Corporate Headquarters Lease
11. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Held on November 11, 2008 at 5:00 am ... / 9:00 pm (Beijing/Hong Kong), SHENYANG, China, Oct. ... leading China-based biotechnology company focused on,researching, developing, manufacturing and ... financial results,for the third quarter ended September 30, 2008 ...
... Gaining a first-cycle,approval for a new molecular entity ... revenue on average, according to a new analysis ... (Nasdaq: PRXL ),and leading global life sciences ... to the PAREXEL Consulting,analysis, 60 percent of sales ...
... of Standards and Technology (NIST) and JILA, a ... Colorado (CU) at Boulder, have made the first ... in delicate measurements of microwave signals, the new ... quantum computing and communications systems. , Conventional amplifiers ...
Cached Biology Technology:3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5First tunable, 'noiseless' amplifier may boost quantum computing, communications 2
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... the University of Pittsburgh received two grants totaling more ... (NIH) to explore new methods for cultivating replacement cells ... five-year Transformative R01 (T-R01) grant presented to Eric Lagasse, ... and a researcher in Pitt and UPMC,s jointly operated ...
... Ridgeland, Mississippi, a graduate student in biological sciences at ... Health (NIH) Graduate Research Fellowship for her study of ... a mosquito-borne disease that can cause seizures, coma, paralysis, ... a wildlife veterinarian, is pursuing her doctoral degree. The ...
... Mich. Technology that could enhance plants, seed oil ... licensed to BASF Plant Science under an exclusive commercial ... collaboration, a plant gene that regulates oil accumulation in ... MSU Technologies, Michigan State,s technology transfer office. The gene ...
Cached Biology News:Pitt researchers net $5 million from NIH to explore better ways to grow cells 2Pitt researchers net $5 million from NIH to explore better ways to grow cells 3NIH fellowship recipient to study disease ecology 2MSU licenses plant oil enhancement technology to BASF Plant Science 2
...
... Solution is a comprehensive suite of ... specifically designed to reliably extract biological ... genomic studies containing thousands of samples, ... efficient and will analyze large data ...
Biotin or fluorescent labels can be attached and the stoichiometry of protein labeling determined....
...
Biology Products: